At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 64 enrolled
Drug / intervention
Exparel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Liposomal Bupivacaine in Arthroscopic Rotator Cuff Repair
In Brief
A Phase 4 clinical trial evaluating Exparel and Ropivacaine for Rotator Cuff Injury. Completed, enrolled 64 participants across 1 site.
Detailed Summary
To assess the efficacy of interscalene liposomal bupivacaine in controlling postoperative pain scores, oral morphine equivalents and sleep quality after arthroscopic rotator cuff repair surgery as compared to interscalene catheter.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRotator Cuff Injury
CountriesUnited States
CollaboratorsPacira Pharmaceuticals, Inc
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartDec 2019
Primary CompletionJan 2022
TodayJul 2026
First PostedNov 13, 2018
Enrollment StartDec 15, 2019
Primary CompletionJan 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.6 years ago
Interventions
Expareldrug
A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
Ropivacainedrug
A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain